Target and Genmab Show Strength as S&P 500 Falls — JournalArta Global

Target (TGT) and Genmab (GEN) showed relative strength against the S&P 500's record weekly loss. Target raised its earnings forecast to $10.65–$11.40, while Genmab reported positive cancer trial results. Other stocks mentioned include Cheesecake Factory (CAKE), Netskope (NK), and Welltower (WELL).

Original reporting
Published Nov 22, 2026, 11:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 22, 2026, 11:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Target and Genmab Show Strength as S&P 500 Falls — JournalArta Global — source image
Decision brief

The 30-second read

$TGTBullishMed
01

Why it matters

The highlighted companies each delivered distinct catalysts—Target's earnings outlook, Genmab's trial data, and Welltower's fund‑flow growth—offering traders sector‑specific opportunities.

02

Market read

In a weak broad market, these stocks showed resilience, making them potential short‑term plays for traders seeking upside or defensive positions.

03

What to watch

Potential supply‑chain constraints for Target's Fun 101 category and regulatory review timelines for Genmab's drugs.

Relevance 8/10Novelty 8/10Timing: this week

Background

The S&P 500 posted its worst weekly point loss on record, prompting a relative‑strength scan that highlighted five stocks across diverse sectors.

Company-level read

Ticker impact

$TGTBullishHigh confidence
Context

Target raised its full‑year EPS forecast to $10.65‑$11.40, prompting a 2.7% weekly share rise.

Expected impact

upward pressure as investors price in higher earnings expectations

Evidence & confidence

Guidance lifts earnings multiples; analysts already note strong comparable‑store growth.

$GENNeutralMedium confidence
Context

Genmab reported positive cancer‑trial data, including a 50% death‑risk reduction for head‑and‑neck patients, after a 60% October surge.

Expected impact

potential short‑term pressure as market digests trial data and prior rally

Evidence & confidence

Trial data is positive but the stock already ran up sharply, leading to modest pull‑back.

$WELLBullishMedium confidence
Context

Welltower posted 25% growth in normalized funds from operations and 38% revenue growth in Q3, noting $21 bn of investments for the year.

Expected impact

upward bias as investors value higher NOI growth

Evidence & confidence

Robust fund‑flow growth and rent‑increase driven earnings support a positive outlook.

Market effects

Retail earnings uplift may lift consumer‑discretionary; biotech trial success adds optimism to oncology pipelines.

U.S. retail and REITs benefit; European biotech gains attention from trial data.

Guidance raise and trial results contribute to broader market rotation toward growth and health‑care themes.

Counterpoint

Target's guidance may be overly optimistic given inventory pressures; Genmab's trial data may not translate to commercial success yet.

Key entities

  • Target

    U.S. big‑box retailer with updated earnings guidance.

  • Genmab

    Danish oncology company reporting positive trial outcomes.

  • Welltower

    Senior‑housing REIT with strong Q3 fund‑flow growth.

Related articles

$TGTHighAI 8/10

Target Is Up More Than 50% This Year, but $1,000 From Five Years Ago Is Still Worth Less Than $850

Target (TGT) shares rose 75.56% year-to-date, outperforming the S&P 500. Despite this, five-year returns are negative. In Q3 2026, revenue was $104.78B, net income dropped 9.44%, and comparable sales fell 2.6%. CEO Michael Fiddelke's turnaround efforts showed progress with Q3 2026 comparable sales up 5.6% and adjusted EPS of $2.65. Tariff refunds contributed $2.14 per share. The stock's performance varies significantly based on investment timing.

$TGTMed

Target Beauty Sales Surge 9.1%, but Is Its Retail Recovery Real?

Target reported Q3 adjusted EPS of $2.65, beating estimates by $0.58, with revenue of $27.07 billion. Beauty sales surged 9.1%, but the company is rebounding from a 2025 slump. A $301 million tariff refund contributed significantly to earnings. Shares rose 4.01% post-earnings. The success of its new Target Beauty Studio concept remains to be seen.

$TGTMedAI 8/10

Target Turnaround Lifts Comps 5.6% as Traffic Beats Walmart

Target reported Q3 comparable sales growth of 5.6%, traffic growth of 5%, and net sales growth of 7.1% under CEO Michael Fiddelke's turnaround strategy. Food and beverage grew nearly 7% and beauty 9%, while private label spending fell 7%. Target plans $5B-$6B in capital spending next year, focusing on store expansion and technology. According to Numerator, Target gained 21M store trips, while Walmart and Kroger saw declines.